Does 5-Amino-1MQ Actually Burn Fat? (No Human Trials Yet)

5-amino-1MQ is the compound your favourite peptide vendor is suddenly very excited about. It's oral, it's cheap, it promises fat loss without touching your appetite, and it rides the NAD+ longevity wave that biohackers love. The pitch is genuinely interesting: block one enzyme inside your fat cells and they start burning energy instead of storing it. The problem is the gap between that pitch and what has actually been proven in a human being, which right now is nothing. So let's do what nobody selling it will: separate the real mechanism from the marketing, look at exactly what the animal data shows, and lay out the bloodwork to run if you decide to try it anyway.

What 5-amino-1MQ actually is

First, kill a common myth: 5-amino-1MQ is not a peptide. It's a small synthetic molecule, a quinolinium compound, that happens to be sold alongside peptides because the same research-chem vendors carry it. 5-amino-1MQ is a selective inhibitor of an enzyme called NNMT, nicotinamide N-methyltransferase, developed by Watowich and colleagues at the University of Texas Medical Branch.

Here's why blocking that enzyme matters. NNMT takes nicotinamide (a form of vitamin B3) and methylates it into 1-methylnicotinamide for excretion, using SAM (S-adenosylmethionine, your body's universal methyl donor) to do it. That creates a double drain. Nicotinamide is the main raw material for the NAD+ salvage pathway, which produces more than 85% of your cellular NAD+. So every time NNMT pulls nicotinamide off to make 1-methylnicotinamide, it's competing directly with NAD+ regeneration. At the same time, it burns through SAM.

The kicker is that NNMT is heavily overexpressed in the white fat tissue of obese and insulin-resistant people. Type 2 diabetics show roughly twofold higher NNMT in fat compared to lean controls, and NNMT levels track inversely with insulin sensitivity (Kannt et al., 2015). In other words, in the people who least want it, this enzyme is running hot and draining the NAD+ pool inside their fat cells. 5-amino-1MQ is the intervention that turns that drain off.

Click to expand

How blocking NNMT raises NAD+ and burns fat

The mechanism chain is clean. Block NNMT, and nicotinamide is no longer wasted on 1-methylnicotinamide. It flows back into the salvage pathway, NAD+ rises inside the fat cell, and that extra NAD+ feeds SIRT1, the "longevity" enzyme that depends on it. Activated SIRT1 deacetylates PGC-1alpha and related targets, which cranks up mitochondrial activity, fatty acid oxidation, and energy expenditure. Meanwhile the SAM that NNMT would have consumed is preserved, which feeds polyamine cycling, a futile loop that burns acetyl-CoA and adds a bit of thermogenesis on top.

The result, at least in a fat cell, is a shift from storing energy to spending it. This is a genuinely different lever from almost everything else in the fat-loss world. GLP-1 drugs like semaglutide work mostly by killing your appetite. Stimulants and beta-agonists like clenbuterol drive thermogenesis through your nervous system and your heart rate. 5-amino-1MQ does neither. It works inside the adipocyte itself, which is why the animal weight loss showed up without any drop in food intake. For a bodybuilder who needs to keep eating to hold muscle, an appetite-neutral fat-loss mechanism is a genuinely attractive idea.

That's the theory, and it's a good one. Now the hard part.

Does it actually work? The honest answer

Here is the sentence no vendor will print: as of 2026, there are zero completed, published human clinical trials of 5-amino-1MQ. None. Everything you have read about it being a "proven" fat-loss compound traces back to mice and cell cultures.

What we do have is real and reasonably consistent, so let's give it credit where it's due:

The foundational work came from genetic knockdown. Kraus and colleagues silenced NNMT in the fat and liver of diet-induced obese mice and saw a 47% reduction in relative fat mass and a 15% increase in lean mass, alongside higher NAD+ and SAM (Kraus et al., 2014). That is a dramatic result, but read it carefully: that was gene silencing, essentially turning the enzyme off at the DNA level, not a pill.

The closest thing to "the actual compound" is Neelakantan's 2018 paper, the first to test 5-amino-1MQ as a small molecule in living animals. Dosed at 20 mg/kg subcutaneously three times a day for 11 days, it reduced body weight and white fat mass, shrank adipocytes, and lowered cholesterol in obese mice, with no change in food intake and no obvious side effects (Neelakantan et al., 2018). A 2024 follow-up pushed the dose to 32 mg/kg/day and reported fat-mass gain suppressed by roughly 72% versus controls, with lean mass unchanged, improved glucose tolerance, lower triglycerides, and less fatty liver (Babula et al., 2024).

So the preclinical signal is genuine and has been replicated across multiple labs and multiple NNMT-inhibitor compounds. This is not junk science. But "real signal in mice" and "works in humans" are different universes, and there are specific reasons to be cautious here.

Why mouse fat loss may not become your fat loss

Lab mice are housed below their comfortable temperature, so they burn 20 to 30% of their energy just staying warm, a thermogenic load humans basically don't have. Drugs that nudge that system can produce mouse weight loss through a mechanism with no real human equivalent. On top of that, diet-induced obese mice are genetically identical, sedentary, and severely fat from a 45 to 60% fat diet. That animal looks nothing like a trained lifter at 12% body fat. Whether unclogging the NNMT drain does anything meaningful in someone who is already lean is a complete unknown, and the community experience reflects that: roughly 40% of users report feeling nothing, and the people who do respond tend to already be lean.

There's also a delivery problem nobody mentions. Every published mouse study injected the compound. Almost everyone in the community swallows it as a capsule, and the oral bioavailability of 5-amino-1MQ in humans has never been measured. You could be taking a dose that produces nothing like the plasma levels the mouse studies used.

5-amino-1MQ vs MOTS-C vs retatrutide

The most useful way to place 5-amino-1MQ is next to the other fat-loss tools enhanced athletes actually compare it to. The single most important axis is not mechanism, it's evidence.

That retatrutide number is real human data: a 48-week phase 2 trial hit 24.2% mean weight loss at the top dose (Jastreboff et al., 2023). MOTS-C sits in the middle, with a defined mechanism (it activates AMPK in muscle, originally described by Lee et al., 2015) and some early human signals but no fat-loss intervention trial. 5-amino-1MQ is at the back of the pack on evidence and the front on convenience, since it's the only oral one.

Worth noting: MOTS-C and 5-amino-1MQ both end up boosting NAD+/SIRT1, but by completely different routes and in different tissues, so they aren't redundant. If you want the deeper head-to-head, see our MOTS-C and SS-31 guide and the retatrutide bloodwork guide. The honest verdict: retatrutide if you want a proven lever, MOTS-C as a muscle-friendly adjunct, and 5-amino-1MQ as a "watch this space" experiment.

Dosing reality

Because there are no human pharmacokinetic studies, every dose you'll see quoted is a guess. Here's the honest version of where those guesses come from.

Run the mouse dose through standard allometric scaling (the 20 mg/kg mouse dose, adjusted for body surface area) and you land around 1.6 mg/kg, or roughly 130 mg/day for an 80 kg person. That happens to line up with the community's upper-end oral dosing, which gives the numbers a false sense of precision. They are not validated, because nobody has measured whether an oral capsule even reaches the plasma levels the injected mouse studies achieved.

What people actually run, anecdotally:

• Oral: 50 mg/day to start, 100 mg/day as a standard, 150 mg/day at the aggressive end, often split morning and evening
• Injectable (subcutaneous): 2.5 to 5 mg/day, occasionally higher
• Cycle length: 8 to 12 weeks on, with a 4 to 6 week break
• Effects, when reported, tend to show up around weeks 5 to 8

One genuine sourcing detail worth knowing: the chloride salt used in university research is considered more active than the iodide salt that most vendors sell as a research chemical. And if you load up on methyl donors (SAMe, methylated B12, methylfolate), you may blunt the effect by flooding the system with the exact SAM that NNMT inhibition is supposed to preserve.

What bloodwork to run on 5-amino-1MQ

This is where 5-amino-1MQ actually fits the VitalMetrics philosophy. With no human trials, your own bloodwork is the only feedback loop you have. Since the compound targets fat metabolism and insulin sensitivity, that's exactly what you track.

Click to expand

Get a baseline before you start, then recheck at the end of the cycle, and ideally at a midpoint around week 4 to 6. The panel:

Fasting glucose and fasting insulin, run together. Insulin is the more sensitive early signal. Optimal fasting insulin is under 5 mIU/L; above 10 mIU/L deserves attention even if glucose looks fine.

HOMA-IR is the headline metric for anything claiming to improve insulin sensitivity. The math: HOMA-IR = fasting insulin (mIU/L) multiplied by fasting glucose (mmol/L), divided by 22.5. So glucose of 5.0 and insulin of 6 gives (5.0 x 6) / 22.5 = 1.33. Under 1.0 is excellent; flag anything trending over 2.0. If this number falls over a cycle, that's your most meaningful efficacy signal.

HbA1c reflects 8 to 12 weeks of average glucose, so it's an end-of-cycle metric, not a mid-cycle check. Interestingly, mouse knockout work found NNMT loss improved insulin sensitivity without changing glucose tolerance (Brachs et al., 2019), which is exactly why HOMA-IR and fasting insulin are better readouts here than HbA1c alone.

A full lipid panel: HDL, LDL, and triglycerides. The animal data showed lower cholesterol and triglycerides; in humans this is unproven, but triglycerides are a sensitive metabolic marker worth watching.

ALT and AST for liver, since the compound acts heavily on the liver and there's no human safety data. No hepatotoxicity showed in animals, but you verify that in yourself.

hs-CRP as a secondary signal. NNMT is tied to metabolic inflammation, so a falling hs-CRP would be a supportive sign.

If you want to build the testing habit properly, the SARMs and peptides bloodwork guide covers the full baseline-and-recheck approach this compound class needs.

Stacking it: where it might earn a place

Nobody runs 5-amino-1MQ in isolation, so let's be real about the stacks, while remembering there is zero human combination data for any of these.

The strongest rationale is as metabolic insurance against growth hormone secretagogues. MK-677 reliably raises blood sugar: in a controlled trial of healthy elderly subjects, 25 mg/day pushed fasting glucose up 26%, from 5.4 to 6.8 mmol/L in a month (Chapman et al., 1996), and reviews confirm worsened insulin sensitivity across studies (Sigalos & Pastuszak, 2018). Since 5-amino-1MQ's whole pitch is NAD+/SIRT1-driven insulin sensitisation, using it to offset that creep is mechanistically coherent. It's also the strongest hook in this whole article, so let me be blunt about the limit: coherent mechanism is not evidence. The primary fixes for GH-induced glucose problems are dose reduction and diet, covered in our GH insulin resistance guide and the MK-677 blood sugar article. 5-amino-1MQ is, at best, an adjunct.

It's also stacked with GLP-1 drugs and with GH peptides like CJC-1295 and ipamorelin. The GLP-1 logic is that appetite suppression from tirzepatide or semaglutide handles intake while a cellular fat-mobilisation tool handles the harder visceral fat later in a cut, a niche where tesamorelin already has actual human data (see the tesamorelin visceral fat guide and our GLP-1 bloodwork guide). The MOTS-C pairing has a neat theoretical fit too: MOTS-C raises NAD+ demand through AMPK, while 5-amino-1MQ protects the NAD+ pool by blocking its drain.

What if I'm on MK-677 and my glucose is creeping up?

Concrete scenario, because this is the most common real reason people reach for this compound. Say you started MK-677 with a HOMA-IR of 1.1, and twelve weeks in it's 2.8 with fasting insulin climbing. That's a measurable, real signal of GH-driven insulin resistance. The correct first moves are to drop the MK-677 dose or tighten your diet and carbs. Adding 5-amino-1MQ on top is plausible and some people do it, but you'd treat it as an experiment: add it, hold everything else constant, and recheck HOMA-IR in 6 to 8 weeks. If the number doesn't move, you have your answer, and you've spent the money to learn it rather than to believe a vendor.

Practical recommendations

If you're going to run 5-amino-1MQ, do it like a scientist, not a customer:

• Get a full baseline panel first. Without it, you cannot tell whether the compound did anything.
• Start at the low end (50 mg oral) and give it the full 5 to 8 weeks responders report before judging.
• Recheck HOMA-IR, lipids, and liver enzymes at the end. Let the numbers, not the vibes, decide whether it stays in your protocol.
• Don't stack it with high-dose methyl donors that may cancel the mechanism.
• Accept the real possibility it does nothing for you, especially if you're already lean. A 40% non-responder rate in an enthusiastic community is not a great sign.
• If you're drug tested, skip it entirely. It's WADA-prohibited.

Key takeaways

• 5-amino-1MQ is a small-molecule NNMT inhibitor (not a peptide) that raises NAD+ and SIRT1 inside fat cells to push them toward burning energy, without affecting appetite.
• The mechanism is legitimate and the mouse data is real and replicated, but there are no completed human trials, no measured oral bioavailability, and no human safety profile.
• Mouse fat-loss results may not translate: lab mice run on thermogenesis humans don't have, and the obese-mouse model looks nothing like a lean trained athlete.
• Community dosing (50 to 150 mg oral) is extrapolated guesswork; about 40% of users report no effect, and responders tend to already be lean.
• The honest use case is metabolic insurance against MK-677/GH insulin resistance, but that's mechanism, not proof.
• Run baseline and end-of-cycle bloodwork: fasting glucose, fasting insulin, HOMA-IR, HbA1c, lipids, ALT/AST, hs-CRP. It's WADA-banned, so tested athletes should avoid it.

---

References

1. Kraus, D., Yang, Q., Kong, D., Banks, A. S., Zhang, L., Rodgers, J. T., et al. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258-262. PubMed
2. Neelakantan, H., Vance, V., Wetzel, M. D., Wang, H. L., McHardy, S. F., Finnerty, C. C., Hommel, J. D., & Watowich, S. J. (2018). Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology, 147, 141-152. PubMed
3. Babula, J. J., Bui, D., Stevenson, H. L., Watowich, S. J., & Neelakantan, H. (2024). Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism, 26(11), 5272-5282. PubMed
4. Kannt, A., Pfenninger, A., Teichert, L., Tönjes, A., Dietrich, A., Schön, M. R., Klöting, N., & Blüher, M. (2015). Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia, 58(4), 799-808. PubMed
5. Brachs, S., Polack, J., Brachs, M., et al. (2019). Genetic nicotinamide N-methyltransferase (Nnmt) deficiency in male mice improves insulin sensitivity in diet-induced obesity but does not affect glucose tolerance. Diabetes, 68(3), 527-540. PubMed
6. Lee, C., Zeng, J., Drew, B. G., Sallam, T., Martin-Montalvo, A., Wan, J., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443-454. PubMed
7. Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity: A phase 2 trial. New England Journal of Medicine, 389(6), 514-526. PubMed
8. Chapman, I. M., Bach, M. A., Van Cauter, E., Farmer, M., Krupa, D., Taylor, A. M., & Thorner, M. O. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism, 81(12), 4249-4257. PubMed
9. Sigalos, J. T., & Pastuszak, A. W. (2018). The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 6(1), 45-53. PubMed